American Journal of Kidney Diseases

Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD

By Janinne Ortega-Montiel, Wajd Alkabbani, Georg Hahn, Julie M. Paik

Cohort study of 22,328 peopleInterventions

The paper

Janinne Ortega-Montiel, Wajd Alkabbani, Georg Hahn, Julie M. Paik

Brigham and Women's Hospital

American Journal of Kidney Diseases, 21 Sep 2026

doi.org/10.1053/j.ajkd.2026.06.013 PubMed 42767321

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Frontiers in Endocrinology4 Oct 2026
Underweight is linked to higher kidney disease risk in diabetes